Lessons from an unfavorable gene therapy trial for Duchenne muscle dystrophy

.Nature Medication, Published online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec acquired FDA approval after a damaging trial, which highlights the various difficulties and obstacles of drug growth within this setup.

Articles You Can Be Interested In

• Advertising
• Cultural Events
• Hospitality
• Health Tips
• Tech Updates
• Home Improvement
• Holidays
• Insurance
• Management
• Investment
• Mental Health
• Mental Health
• Gardening
• Robotics
• Teamwork
• Psychology
• Customer Service
• Data Science
• Customer Service
• Logistics